82
Participants
Start Date
November 29, 2012
Primary Completion Date
May 21, 2018
Study Completion Date
August 23, 2019
Obinutuzumab
Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
Venetoclax
Participants will receive multiple doses of venetoclax orally once daily.
Weill Cornell Medical College-New York Presbyterian Hospital, New York
SCRI-Tennessee Oncology, Nashville
Ohio State University Comprehensive Cancer Center, Columbus
The Methodist Hospital Research Institute; Academic Office of Clinical Trials, Houston
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
UCSD Moores Cancer Center, La Jolla
Oncology Associates of Oregon, Springfield
St James University Hospital, Leeds
Leicester Royal Infirmary NHS Trust, Leicester
Barts and The London School of Medicine and Dentistry; Queen Mary, University of London, London
Lead Sponsor
AbbVie (prior sponsor, Abbott)
INDUSTRY
Genentech, Inc.
INDUSTRY